Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation

Zhuang, Weitao; Zhang, Chao; Tang, Yong; Tian, Dan; Lan, Zihua; Zeng, Cheng; Qiao, Guibin

doi:10.2147/ott.s328839

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Giuseppina Improta et al reported the TKI sensitivity in a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations, Which described two advanced LADC patients with EGFR p.L747_T751delinsP mutation and p.T751_I759delinsS respectively who have only 2-month PFS on gefitinib therapy (22). However, an IIIB Squamous cell lung cancer (SqCLC) patient harboring EGFR Exon 19 E746_S752delinsV mutation could benefit from targeted therapies of gefitinib, and no evidence of disease was found for up to 20 months, which indicated that the first-generation EGFR TKIs might be a good choice for advanced SqCLC patients and different types of uncommon exon 19 mutations have a different response to TKIs (23). Besides, Robichaux et al described an approach that separated the EGFR mutations into four subgroups based on structure-function and to predict the EGFR TKIs sensitivity for uncommon EGFR mutations (6).…”

Section: Discussionmentioning

confidence: 99%

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

Meng,

Li,

Zhang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is an established driver gene in non-small cell lung cancer (NSCLC) and the common Exon 19 del mutation (p.E746_A750 del) has exhibited remarkable responses for EGFR tyrosine kinase inhibitors (TKIs). However, there is even less comprehension of the treatment strategy in NSCLC patients harboring uncommon Exon 19 delins mutation. Here, we identified three novel EGFR Exon 19 mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA), and described the clinical treatment process. To our knowledge, the EGFR p.E746_S752delinsI mutation of the patient with advanced NSCLC could benefit from the treatment with Icotinib. Otherwise, for the NSCLC patients with early-stage, one harboring p.T751_I759delinsG mutation had an excellent recovery and the other harboring p.L747_S752delinsAA experienced a relapse after receiving horacoscopic radical resection, which means the patients with different Exon 19 delins mutation might have different prognosis. Our study also demonstrated that next-generation sequencing (NGS) is a crucial tool in guiding clinical treatment decisions in NSCLC. Furthermore, the real incidence of these mutation is not known, the routinely use of NGS surely will increase the detection of EGFR del-ins respect to the old tools used to screen for EGFR mutations.

show abstract

Section: Discussionmentioning

confidence: 99%